Integrated Filing — IndAS



General information about company

Scrip Code 532612
NSE Symbol INDOCO
MSEI Symbol NOTLISTED
ISIN INE873D01024
Name of company INDOCO REMEDIES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 03-02-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 16-01-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Third quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment PHARMACEUTICALS
Start date and time of board meeting 03-02-2026   11:05:00
End date and time of board meeting 03-02-2026   11:50:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
The Company does not have any debt securities and there are no defaults on loan taken by the Company for the quarter and nine months ended 31st December, 2025. Hence the said disclosure is not applicable to the Company.



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-10-2025 01-04-2025
B Date of end of reporting period 31-12-2025 31-12-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 40,051.00 1,23,694.00
Other income 717.00 1,929.00
Total income 40,768.00 1,25,623.00
2 Expenses
(a) Cost of materials consumed 8,119.00 25,498.00
(b) Purchases of stock-in-trade 3,299.00 11,104.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (159.00) (338.00)
(d) Employee benefit expense 9,881.00 29,265.00
(e) Finance costs 2,015.00 6,577.00
(f) Depreciation, depletion and amortisation expense 2,736.00 8,019.00
(f) Other Expenses
1 RESEARCH & DEVELOPMENT EXPENSES 1,831.00 6,178.00
2 OTHER EXPENSES 14,490.00 42,575.00
Total other expenses 16,321.00 48,753.00
Total expenses 42,212.00 1,28,878.00
3 Total profit before exceptional items and tax (1,444.00) (3,255.00)
4 Exceptional items (601.00) (654.00)
5 Total profit before tax (2,045.00) (3,909.00)
6 Tax expense
7 Current tax 0.00 0.00
8 Deferred tax (45.00) (608.00)
9 Total tax expenses (45.00) (608.00)
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations (2,000.00) (3,301.00)
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period (2,000.00) (3,301.00)
17 Other comprehensive income net of taxes (15.00) 83.00
18 Total Comprehensive Income for the period (2,015.00) (3,218.00)
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 1,845.00 1,845.00
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations -2.17 -3.58
Diluted earnings (loss) per share from continuing operations -2.17 -3.58
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -2.17 -3.58
Diluted earnings (loss) per share from continuing and discontinued operations -2.17 -3.58
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The unaudited Standalone Results for the Quarter and Nine Months ended 31st December, 2025 have been reviewed by the Audit committee and approved by the Board of Director of the Company at its meeting held on 03rd February, 2026. The Statutory Auditors have expressed an Unmodified Audit opinion on these unaudited Standalone Financial Results. 2. The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable. 3.The company has only one primary reportable segment of activity, namely, Pharmaceuticals. 4.Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows: Net Sales Quarter Quater Quarter Nine months Nine months Year & ended ended ended ended ended ended Income from 31.12.2025 30.09.2025 31.12.2024 31.12.2025 31.12.2024 31.03.2025 Operations (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) India 23,060 24,735 23,935 70,050 69,959 91,598 Outside India 15,897 18,195 12,556 50,398 45,412 57,880 Total 38,957 42,930 36,491 1,20,448 1,15,371 1,49,478 5. The statutory auditors of the Company have carried out limited review of the financial results for the quarter ended 31st December,2025. 6(*) Exceptional items includes : (a) Consideration received Rs. 253 lakhs for grant to use exclusive, perpetual and irrevocable license rights in respect of trademarks of the company, (b) Loss amounting to Rs. 213 lakhs on sale and leaseback of its Non current Assets, and, (c) Impact of past period employee benefit liability amounting to Rs. 694 lakhs due to implementation of the New Labour Codes. 7. Effective 21 November, 2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes'. The Company has assessed the financial implications of these changes which has resulted in increase in gratuity liability arising out of past service cost and increase in leave liability by Rs. 694 lakhs primarily arising due to change in definition of wages for employees and contract labours. Considering the materiality and nonrecurring nature of this impact, the Company has presented such incremental impact under 'Exceptional Item in the standalone financial results for the quarter and nine months ended 31st December, 2025. The Company continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted in accordance with applicable accounting standards.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-10-2025 01-04-2025
Date of end of reporting period 31-12-2025 31-12-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-10-2025 01-04-2025
B Date of end of reporting period 31-12-2025 31-12-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT & LOSS (75.00) (225.00)
Total Amount of items that will not be reclassified to profit and loss (75.00) (225.00)
2 Income tax relating to items that will not be reclassified to profit or loss (19.00) (57.00)
3 Amount of items that will be reclassified to profit and loss
1 ITEMS THAT MAY BE RECLASSIFIED TO PROFIT & LOSS 54.00 335.00
Total Amount of items that will be reclassified to profit and loss 54.00 335.00
4 Income tax relating to items that will be reclassified to profit or loss 13.00 84.00
5 Total Other comprehensive income (15.00) 83.00